HPV vaccination after allogeneic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 18–45 who have received an allogeneic stem cell transplant are enrolled and receive the 9‑valent HPV vaccine (Gardasil 9) either early or later after transplantation. The main outcome is the antigen‑specific antibody response measured after the vaccine series to compare immune recovery by timing. Key exclusion criteria include severe thrombocytopenia, grade III–IV acute GVHD, extensive chronic GVHD on multiple systemic therapies, recent rituximab or recent IV/SC immunoglobulin, and pregnancy. The multicenter trial is conducted at three Swedish university hospitals and follows participants through the vaccination schedule and antibody testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Recipient of AlloSCT from related or unrelated donor.
* Adults (men and women) ≥18 years up to and including 45 years of age for vaccination.
* Patients can be included regardless of prior HPV vaccination prior to transplantation

Exclusion Criteria:

* Severe thrombocytopenia (under 50 x 10\^9) not allowing intramuscular injection
* Severe acute GvHD grade III-IV.
* Extensive chronic GvHD requiring treatment with prednisone doses above 0.7 mg/kg/day plus at least two other systemic treatments against GvHD (for example ruxolitinib or photopheresis).
* Prednisone doses above 1mg/kg/day at study start.
* Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion.
* Treatment within 3 months before start of vaccination with iv or sc immunoglobulin.
* Pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose.
* Treatment with blood thinning medication contraindicating intramuscular injection
* Allergy against Gardasil 9

Where it's running

• Uppsala University Hospital
  Uppsala, Region Uppsala, Sweden Recruiting
• Linköping University Hospital
  Linköping, Region Östergötaland, Sweden Recruiting
• Sahlgrenska University Hospital
  Gothenburg, Västra Götalands Region, Sweden Recruiting
• Skåne's University Hospital
  Lund, Region Skåne, Sweden Not yet recruiting
• Karolinska University Hospital
  Stockholm, Region Stockholm, Sweden Not yet recruiting

Study contacts

• Study coordinator: Sigrun Einarsdottir, MD, PhD
• Email: sigrun.einarsdottir@vgregion.se
• Phone: 0046313427358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• Proton Therapy for Mediastinal Lymphoma in Denmark

  This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Select A State · NCT07817641

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• AMX-883 in AML and high-risk MDS: a first-in-class dosing study

  This early-stage study tests AMX-883 alone and with another drug to see if it is safe and shows early signs of benefit in people with AML or high-risk MDS.

  Recruiting at 3 sites Phase 1 Amphista Therapeutics Ltd · New York, New York and 2 other locations · NCT07723703

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.